Effect of cisplatin on proteasome activity

Cisplatin is a chemotherapy drug. We report that cisplatin inhibits in dose-dependent fashion the enzymatic proteasome activities. Cisplatin administration to neuroblastoma cells also brings about a loss of proteasome activity followed by proteasome de novo synthesis. Finally, the co-administration of lactacystin (specific proteasome inhibitor) and cisplatin enhances cisplatin cytotoxicity.153